Myoclonus

Current Treatment Options in Neurology

Volumn 10, Issue 3, 2008, Pages 222-229

  Chang, Victoria C ^a   Frucht, Steven J ^b  

^a NEUROLOGICAL INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; CLONAZEPAM; ETIRACETAM; OXYBATE SODIUM; PIRACETAM; PRIMIDONE; VALPROIC ACID;

ATAXIA; BEHAVIOR DISORDER; BRAIN DEPTH STIMULATION; BRAIN ELECTROPHYSIOLOGY; DIFFUSION TENSOR IMAGING; DISEASE CLASSIFICATION; DIZZINESS; DROWSINESS; DRUG CHOICE; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DYSTONIA; EMERGENCY TREATMENT; FATIGUE; FLAPPING TREMOR; HEALTH CARE COST; HUMAN; MYOCLONUS; NAUSEA; ORTHODONTIC DEVICE; PALATOPHARYNGEAL INCOMPETENCE; PARKINSONISM; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT CONTRAINDICATION; TREMOR; UNSPECIFIED SIDE EFFECT; VERTIGO; VOMITING;

EID: 56349136377     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-008-0024-y     Document Type: Review

References (43)

1. Marsden CD, Hallett M, Fahn S: The nosology and pathophysiology of myoclonus. In Movement Disorders. Edited by Marsden CD, Fahn S. London: Butterworth; 1982:196-248.
2. Fahn S: Definition and classification of myoclonus. In Advances in Neurology. Edited by Fahn S. New York: Raven Press; 1986:1-5.
3. Deuschl G, Toro C, Valls-Solé J, et al.: Symptomatic and essential palatal tremor. 1. Clinical, physiological, and MRI analysis. Brain 1994, 117:775-788.
4. Brown P, Thompson PD, Rothwell JC, et al.: Axial myoclonus of propriospinal origin. Brain 1991, 114:197-214.
5. Grinker RR, Serota H, Stein SI: Myoclonic epilepsy. Arch Neurol Psychiatry 1938, 40:968-980.
6. Shibasaki H, Hallett M: Electrophysiological studies of myoclonus. Muscle Nerve 2005, 31:157-174.
7. Lefaucheur JP: Myoclonus and transcranial magnetic stimulation [review]. Neurophysiol Clin 2006, 36:293-297.
8. Roze E, Apartis E, Vidailhet M, et al.: Propriospinal myoclonus: utility of magnetic resonance diffusion tensor imaging and fiber tracking. Mov Disord 2007, 22:1506-1509.
9. Tai KK, Bhidayasiri R, Truong DD: Post-hypoxic animal model of myoclonus. Parkinsonism Relat Disord 2007, 13:377-381.
10. Van Woert MH, Rosenbaum D: L-5-hydroxytryptophan therapy in myoclonus. Adv Neurol 1979, 26:107-115.
11. Thal LJ, Sharpless NS, Wolfson L, et al.: Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations. Ann Neurol 1980, 7:570-576.
12. Tai KK, Truong DD: Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus. J Neural Transm 2007, 114:1547-1551.
13. Pranzatelli MR, Nadi NS: Mechanism of action of antiepileptic and antimyoclonic drugs. Adv Neurol 1995, 67:329-360.
14. Obeso JA: Therapy of myoclonus. Clin Neurosci 1995, 3:253-257.
15. Striano P, Manganelli F, Boccella P: Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. Mov Disord 2005, 20:1610-1655.
16. Frucht S, Louis E, Chuang C, et al.: A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 2001, 57:1112-1114.
17. Magaudda A, Gelisse P, Genton P: Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations. Epilepsia 2004, 45:678-681.
18. Papacostas S, Kkolou E, Papathanasiou E: Levetiracetam in three cases of progressive myoclonus epilepsy. Pharm World Sci 2007, 29:164-166.
19. Koskiniemi M, Van Vleymen B, Hakamies L, et al.: Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the safety and efficacy of three dosages of oral piracetam with placebo. J Neurol Neurosurg Psychiatry 1998, 64:344-348.
20. Brown P, Steiger MJ, Thompson PD, et al.: Effectiveness of piracetam in cortical myoclonus. Mov Disord 1993, 8:63-68.
21. Ikeda A, Shibasaki H, Tashiro K, et al.: Clinical trial of piracetam in patients with myoclonus: nationwide multi-institutional study in Japan. The Myoclonus/Piracetam Study Group. Mov Disord 1996, 11:691-700.
22. Fahn, S: Posthypoxic action myoclonus: review of the literature and report of two new cases with response to valproate and estrogen. In Advances in Neurology. Edited by Fahn S. New York: Raven Press; 1979:49-84.
23. Frucht S: The clinical spectrum of posthypoxic myoclonus. Mov Disord 2000, 15(Suppl 1):2-7.
24. Frucht S, Bordelon Y, Houghton WH: Marked amelioration of alcohol-responsive posthypoxic myoclonus by gamma-hydroxybutyric acid (Xyrem). Mov Disord 2005, 20:745-751.
25. Jankovic J, Pardo R: Segmental myoclonus. Clinical and pharmacologic study. Arch Neurol 1986, 43:1025-1031.
26. Siniscali A, Mancuso F, Russo E, et al.: Spinal myoclonus responsive to topiramate. Mov Disord 2004, 19:1380-1381.
27. Abraham A, Cogan E, Melamed E, et al.: Successful treatment of truncal myoclonus. Mov Disord 2007, 22:1055-1056.
28. Krause E, Leunig A, Klopstock T, Gürkov R: Treatment of essential palatal myoclonus in a 10-year-old girl with botulinum neurotoxin. Otol Neurotol 2006, 27:672-675.
29. Penney SE, Bruce IA, Saeed SR: Botulinum toxin is effective and safe for palatal tremor: a report of five cases and a review of the literature. J Neurol 2006, 253:857-860.
30. Rubboli G, Tassinari CA. Negative myoclonus. An overview of its clinical features, pathophysiological mechanisms, and management [review]. Neurophysiol Clin 2006, 36:337-343.
31. Gelisse P, Crespel A, Genton P, Baldy-Moulinier M: Dramatic effect of levetiracetam on epileptic negative myoclonus. Acta Neurol Scand 2003, 107:302-303.
32. Oguni H, Uehara I, Tanaka T, et al.: Dramatic effect of ethosuximide on epileptic negative myoclonus: implications for the neurophysiological mechanism. Neuropediatrics 1998, 29:29-34.
33. Pueschel SM, Friedman JH, Shetty T: Myoclonic dystonia. Childs Nerv Syst 1992, 8:61-66.
34. Misbahuddin A, Placzek M, Lennox G, et al.: Myoclonus-dystonia syndrome with severe depression is caused by an exon-skipping mutation in the -̇sarcoglycan gene. Mov Disord 2007, 22:1173-1175.
35. Nygaard TG, Raymond D, Chen C, et al.: Localization of a gene for myoclonus-dystonia to chromosome 7q21-q31. Ann Neurol 1999, 46:794-798.
36. Frucht SJ, Boredlon Y, Houghton WH, et al.: Pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders. Mov Disord 2005, 20:1330-1337.
37. Cif L, Valente EM, Hemm S, et al.: Deep brain stimulation in myoclonus-dystonia syndrome. Mov Disord 2004, 19:724-727.
38. Magariños-Ascone CM, Regidor I, Martinez-Castrillo JC, et al.: Pallidal stimulation relieves myoclonus-dystonia syndrome. J Neurol Neurosurg Psychiatry 2005, 76:989-991.
39. Trottenberg T, Meissner W, Kabus C, et al.: Neurostimulation of the ventral intermediate thalamic nucleus in inherited myoclonus-dystonia syndrome. Mov Disord 2001, 16:769-771.
40. Physicians' Desk Reference, edn 62. Montvale, NJ: Thomson PDR; 2008.
41. Drug Topics Red Book, edn 111. Montvale, NJ: Medical Economics; 2007.
42. Mondria R, de Gier HHW, Boon AJW: New device to control combined lingual and palatal myoclonus. Mov Disord 2007, 22:573-575.
43. Caviness J, Brown P: Myoclonus: current concepts and recent advances. Lancet Neurol 2004, 3:598-607.